reports
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May ...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by diali...
National Australia Bank Limited: 1 director
A director at National Australia Bank Limited bought 4,380 shares at 34.000AUD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
GXO meldet Ergebnisse für das erste Quartal 2024
GXO meldet Ergebnisse für das erste Quartal 2024 Umsatz im ersten Quartal von 2,5 Mrd. USD, 6 % mehr als im Vorjahr; organisches Umsatzwachstum1 von 1 %Neue Geschäftsabschlüsse mit einem Jahresumsatz von ca. 250 Mio. USD im 1. Quartal 2024; Anstieg um 55 % im JahresvergleichVerkaufspipeline erreicht 12-Monats-Hoch von 2,2 Mrd. USDAbschluss der Übernahme von Wincanton am 29. April 2024 GREENWICH, Connecticut, May 09, 2024 (GLOBE NEWSWIRE) -- (NYSE: GXO) hat heute die Ergebnisse für das erste Quartal 2024 bekanntgegeben. Malcolm Wilson, Chief Executive Officer von GXO, dazu: „Wir...
GXO publie ses résultats pour le premier trimestre 2024
GXO publie ses résultats pour le premier trimestre 2024 Chiffre d’affaires arrêté à 2,5 milliards de dollars, soit une hausse de 6 % par rapport à l’année précédente ; et croissance organique1 de 1 %Nouveaux contrats signés pour une valeur de près de 250 millions de dollars de chiffre d’affaires annualisé, soit une progression de 55 % par rapport au premier trimestre 2023Prévisions commerciales à 12 mois de l’ordre de 2,2 milliards de dollarsAcquisition finalisée de Wincanton le 29 avril 2024 GREENWICH, État du Connecticut, 09 mai 2024 (GLOBE NEWSWIRE) -- (NYSE : GXO) publie ce jour ses...
CompoSecure Announces Pricing of Secondary Offering of Shares of Class...
CompoSecure Announces Pricing of Secondary Offering of Shares of Class A Common Stock by Selling Shareholders SOMERSET, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- (“CompoSecure”) (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the pricing of a secondary offering of 7,000,000 shares of its Class A common stock, par value $0.0001 per share, by certain shareholders of the Company (the “Selling Shareholders”) at a price to the public of $6.50 per share for total gross proceeds of $45,500,000 million (the “Offering”). In connection with the...
Outlook Therapeutics® to Report Financial Results for Second Quarter F...
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it will report its financial results for second quarter fiscal year 2024 on Thursday, May 16, 2024. Outlook Therapeutics management will host its inaugur...
Trelleborg AB: 1 director
A director at Trelleborg AB bought 1,600 shares at 36.084USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Bank Ozk: 1 director
A director at Bank Ozk sold 5,875 shares at 47.950USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Eurohold Bulgaria AD: 1 director
A director at Eurohold Bulgaria AD bought 775,000 shares at 0.930BGN and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
UCB SA: 2 directors
Two Directors at UCB SA sold/bought 1,385 shares at 128.760USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
C I Capital Holding For Financial Investments: 1 director
A director at C I Capital Holding For Financial Investments bought 342,000 shares at 0.000EGP and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Gamuda Berhad: 1 director
A director at Gamuda Berhad sold 60,000 shares at 5.450MYR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Egyptian Modern Education Systems: 1 director
A director at Egyptian Modern Education Systems sold 2,609,759 shares at 0.000EGP and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
AFC Gamma, Inc. Announces Financial Results for First Quarter 2024
AFC Gamma, Inc. Announces Financial Results for First Quarter 2024 First quarter 2024 GAAP net loss of $(0.1) million or $(0.01) per basic weighted average common share and Distributable Earnings(1) of $10.0 million or $0.49 per basic weighted average common share Paid dividend of $0.48 per common share for first quarter 2024 WEST PALM BEACH, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AFC Gamma, Inc. (NASDAQ:AFCG) (“AFC Gamma” or the “Company”) today announced its results for the first quarter ended March 31, 2024. AFC Gamma reported generally accepted accounting principles (“GAAP”) net lo...
AGS Enters Into Definitive Agreement To Be Acquired By Brightstar Capi...
AGS Enters Into Definitive Agreement To Be Acquired By Brightstar Capital Partners for Approximately $1.1 Billion LAS VEGAS and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- PlayAGS, Incorporated (NYSE: AGS) (“AGS” or the “Company”), a global gaming supplier of high-performing slot, table, and interactive products, today announced that it has signed a definitive agreement to be acquired by affiliates of Brightstar Capital Partners (“Brightstar”), a middle market private equity firm focused on investing in industrial, manufacturing, and services businesses. The Company’s Board of Dire...
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt...
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the corneaSurrozen’s antibody based Wnt mimetic also increased detectable tear volume production in dry eye disease models SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- (“Surrozen” or t...
Nuvo Group Adds HealthTech Veteran Adriana Machado to Board of Directo...
Nuvo Group Adds HealthTech Veteran Adriana Machado to Board of Directors, Strengthening Company’s Commitment to Transforming Prenatal Care Following Nuvo’s NASDAQ Listing, Addition of Machado Brings Strong Health and Impact Experience to Remote Pregnancy Monitoring Pioneer TEL AVIV, Israel, May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: NUVO) (“Nuvo”), a pioneer in remote pregnancy monitoring, today announced the expansion of its board of directors with the addition of Adriana Machado, who will help guide Nuvo’s mission of addressing health disparities and social determinants of care throug...
Dorel Industries Will Hold a Conference Call to Discuss Its First Quar...
Dorel Industries Will Hold a Conference Call to Discuss Its First Quarter Results MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Dorel Industries, Inc. (TSX: DII.B, DII.A) CONFERENCE CALL:OPEN TO:Analysts, investors and all interested partiesDATE:Friday, May 10, 2024TIME:1:00 PM Eastern TimeCALL:1-800-319-4610 THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKETS OPEN THE SAME DAY THROUGH GLOBENEWSWIRE. Please dial in 15 minutes before the conference begins. If you are unable to call in at this time, you may access a recording of the meeting by calling 1-800-319-6413 and entering the passcod...
Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Heal...
Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm a...
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegter...
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 COPENHAGEN, Denmark, May 09, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at the European Congress of Endocrinology being held May 11-14, 2024, in Stockholm. Topics include an oral presentation of new 2-year results from a post-hoc analy...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.